Enos Bernasconi mostly deals with Internal medicine, Immunology, Cohort study, Acquired immunodeficiency syndrome and Viral load. His studies in Internal medicine integrate themes in fields like Gastroenterology, Surgery and Stavudine. His Immunology research incorporates themes from Odds ratio and Virology.
His Cohort study research is multidisciplinary, relying on both Pharmacotherapy, Survival analysis and Cohort. His Acquired immunodeficiency syndrome study integrates concerns from other disciplines, such as Viral disease, microRNA and Discontinuation. His Viral load research integrates issues from Heritability, Single-nucleotide polymorphism and Phylogenetics.
His primary areas of investigation include Internal medicine, Cohort study, Immunology, Viral load and Virology. The Internal medicine study combines topics in areas such as Gastroenterology, Acquired immunodeficiency syndrome and Surgery. His research in Acquired immunodeficiency syndrome intersects with topics in Viral disease and Epidemiology.
Enos Bernasconi focuses mostly in the field of Cohort study, narrowing it down to matters related to Men who have sex with men and, in some cases, Transmission. His work on Hepatitis C virus, Coinfection and Lamivudine as part of general Immunology study is frequently connected to Institutional repository, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His work in Viral load covers topics such as Antiretroviral therapy which are related to areas like Pediatrics.
His primary areas of study are Internal medicine, Cohort study, Men who have sex with men, Odds ratio and Confidence interval. His Internal medicine study incorporates themes from Gastroenterology and Viral load. The subject of his Viral load research is within the realm of Immunology.
His Cohort study research incorporates elements of Tenofovir alafenamide, Epidemiology, Population study, Regimen and Cohort. His Men who have sex with men study also includes
Enos Bernasconi focuses on Internal medicine, Men who have sex with men, Cohort study, Hepatitis C and Prospective cohort study. The study incorporates disciplines such as Diabetes mellitus and Gastroenterology in addition to Internal medicine. His work focuses on many connections between Cohort study and other disciplines, such as Confidence interval, that overlap with his field of interest in Drug resistance, Mental health and Medical record.
His Hepatitis C study combines topics in areas such as Treatment as prevention, Grazoprevir, Incidence and Hepatitis C virus. His research integrates issues of Transmission, Observational study, Unsafe Sex and Viral load in his study of Prospective cohort study. His Viral load research is under the purview of Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study
Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka.
PLOS ONE (2015)
Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study
Andri Rauch;Zoltán Kutalik;Zoltán Kutalik;Patrick Descombes;Tao Cai.
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
Bruno Ledergerber;M. Egger;V. Erard;R. Weber.
Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study
Barbara Hasse;Bruno Ledergerber;Hansjakob Furrer;Manuel Battegay.
Clinical Infectious Diseases (2011)
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.
Markus Cornberg;Homie A. Razavi;Alfredo Alberti;Enos Bernasconi.
Liver International (2011)
CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years: The Swiss HIV Cohort Study
Gilbert R. Kaufmann;Luc Perrin;Guiseppe Pantaleo;Milos Opravil.
JAMA Internal Medicine (2003)
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Jacques Fellay;Bruno Ledergerber;Enos Bernasconi;Hansjakob Furrer.
The Lancet (2001)
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Christoph D. Spinner;Robert L. Gottlieb;Gerard J. Criner;José Ramón Arribas López.
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Gilbert R. Kaufmann;Hansjakob Furrer;Bruno Ledergerber;Luc Perrin.
Clinical Infectious Diseases (2005)
Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study
R Weber;M Ruppik;M Rickenbach;A Spoerri.
Hiv Medicine (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: